Hi

The impact of under-representation of women in clinical trials is significant and has resulted in an over-representation of serious adverse events and side effects from prescribed medications in women.

Tune into Dr Rachael Sumner, who discusses the issues and the team's luteal phase dosing approach in newly approved clinical trials for negative mood symptom alleviation in Pre-Menstrual Syndrome (PMS) and Pre-Menstrual Dysphoric Disorder (PMDD).

Click to Watch!

Update on Phase 2A Depression Trial Data

The Company will provide secondary data from its recently completed Phase 2A MB22001 microdosing trials in Major Depressive Disorder this month.

Watch Dr Rachael Sumner on Youtube here: https://youtu.be/ha2OqTwldNM?si=T3DEAyq3eIAdoENX

Stay Well!

JUSTIN HANKA

Chief Executive Officer & Co-Founder

MindBio Therapeutics Corp (Frankfurt: WF6), (CNSX: MBIO)

Follow CEO Justin Hanka on LinkedIn:

https://www.linkedin.com/in/justinhanka/

Follow MindBio on LinkedIn: https://www.linkedin.com/company/mindbio-therapeutics/?viewAsMember=true